Hochul's budget threatens cancer care gains for medicaid recipients

Albany—A policy shift quietly embedded within Governor Kathy Hochul’s proposed 2027 budget could significantly curtail access to life-altering biomarker testing for New Yorkers enrolled in Medicaid, reversing progress made just three years ago. The move has ignited a firestorm of protest from cancer survivors and patient advocates who warn of potentially devastating consequences for vulnerable populations.

The promise of precision medicine, now under threat

In 2023, a landmark bill championed by Hochul mandated that insurance providers, including Medicaid, cover biomarker testing—a pivotal advancement in cancer care that analyzes measurable indicators to tailor treatment plans. The technology allows physicians to identify how a patient’s tumor responds to specific therapies, dramatically improving outcomes. But the proposed budget introduces “medical necessity criteria” for Medicaid coverage, a stipulation advocates fear will create unnecessary hurdles and effectively restrict access.

The briefing book outlines the shift, stating that all biomarker testing now requires demonstration of “medical necessity.” This vague phrasing leaves the door open to arbitrary denials, potentially denying patients access to the precise diagnostics that could be the difference between remission and a grim prognosis. The governor’s office, in a prepared statement, insists the proposal is intended to “further ensure patient safety” and aligns with “evidence-based and peer-reviewed guidelines,” while maintaining that biomarker testing remains a covered benefit. However, the subtle language shift has raised serious concerns.

Lexy Mealing, a breast cancer survivor who credits biomarker testing with her recovery, embodies the stakes. “It was life-shattering,” she recounts, recalling her diagnosis five years ago. The testing, she emphasizes, provided her physicians with a “clear, open path” to the most effective treatment, ultimately leading to her current remission. She, alongside dozens of other advocates, rallied outside the governor’s Manhattan office this week, urging lawmakers to reject the proposed changes.

The impact extends far beyond cancer patients. Michael Davoli of the American Cancer Society Cancer Action Network highlights the implications for individuals battling diseases like ALS, for whom biomarker testing holds the promise of future cures. “We've watched for too long as people of color, low-income individuals, and my neighbors disproportionately shoulder the burden of disease like cancer,” adds Jacqueline Nesbit, a Bronx resident and lung cancer survivor. “It's largely because we’ve been shut out of advances like biomarker testing.”

The budgetary maneuver, critics argue, amounts to a cynical attempt to balance the state’s books on the backs of those most in need. “We should not be balancing the state budget on the backs of cancer patients,” Davoli stated firmly, encapsulating the frustration felt by many. The coming weeks will be critical as the legislature debates the budget, and the fate of precision medicine access for countless New Yorkers hangs in the balance.